Munich, Germany, 19 October 2018 - Men and women may need to be treated differently - at least when it comes to some types of cancer. In an analysis (1) to be presented at the ESMO 2018 Congress in Munich, data was pooled from four UK randomised controlled clinical trials (RCTs) of first line chemotherapy in oesophagogastric (OG) cancer, finding significant differences in a number of important side-effects experienced by male and female patients.
Study author Dr. Michael Davidson, Royal Marsden Hospital NHS Foundation Trust, London, said: "We have known for a long time in oncology that there are differences between males and females in the incidence and prognosis of many non gender-specific cancers. We are now also beginning to understand some of the complex cellular, molecular and metabolic differences between the two sexes which influence both cancer development and response to treatment. The clinical question we wanted to answer was whether sex influences the toxicity and efficacy of common chemotherapies administered in oesophageal and gastric cancer. It's the first time that gender-differentiated data has been collected on such a large scale for this tumour type."
The trials selected for this pooled analysis were all evaluating first line chemotherapy regimens for patients with advanced OG cancer. "The four trials we included were large international trials conducted in the UK and Australasia with comparable patient populations and treatments being used," Davidson said. "This allowed us to collate and compare the data." In total 1654 patients were included: 80% were male and 20% were female. A greater proportion of gastric as opposed to junctional or oesophageal cancers were seen in female patients. "These findings are consistent with the incidence and distribution of OG cancers in Western populations," Davidson observed.
Based on the toxicities captured commonly in all four trials, the analysis showed no significant difference between the overall rates of toxicity experienced by men and women. "The data get more interesting once we look at individual toxicity results," Davidson explained. Indeed, women were found to have experienced significantly higher rates of nausea and vomiting, with 89.3% of women versus 78.3% of men experiencing this common toxicity. "This tendency was confirmed on the more serious end of the spectrum, too, with 16.7% of female patients experiencing it at a severity grade 3 or above, compared to 9.5% of males," said Davidson.
Women were also more prone to diarrhoea (53.8% of females compared to 46.9% of males), mouth ulceration (49.5% versus 40.7%) and hair loss (81.4% versus 74.3%) at all grades of severity. By contrast, 49.3% of male patients suffered from peripheral neuropathy - damage to peripheral nerves resulting in loss of sensation - compared to 42.6% of females.
In terms of treatment efficacy, no significant difference was seen in survival between male and female patients. The overall response rate - namely the number of patients achieving a reduction in tumour size on chemotherapy - was higher in males to an extent that approached but did not reach statistical significance.
"Our key finding, therefore, is that men and women treated with similar chemotherapy combinations for OG cancer were affected by a number of different toxicities to varying degrees," Davidson said. "The clinical relevance of this remains to be established. Whilst there is not enough data here to support alternative chemotherapy dosing strategies for men and women, it is useful for clinicians to be aware of such findings in order to refine their treatment in other ways. For example, knowing that women are more likely to experience gastrointestinal side-effects such as nausea and vomiting or diarrhoea may allow for more tailored education to be given to patients, empowering them to report problems early and allowing doctors to introduce supportive measures more proactively and intensively."
Commenting on the results, Prof. Michel Ducreux, from the Institut Gustave Roussy in Villejuif, France, said: "Dissimilarities in men and women's reactions to treatment had already been observed in a number of past clinical trials. Until recently though, because no one could explain why such differences might exist, they tended to be written off as a statistical artefact and remained absent from the discussion. In the clinic, meanwhile, the trends highlighted in this study would have been imperceptible to physicians. Thanks to the large number of patients included, this analysis was able to show statistically significant gender differences in the frequency of several side-effects of chemotherapy. Now, not only must we discuss their implications, we also need to understand the underlying reasons."
Ducreux added: "Going forward, we might consider stratifying patients according to their gender in clinical trials, so as to evaluate the efficacy and tolerance of treatments in each sex from the beginning of drug development. If further studies systematically confirm that women are more prone than men to a wider range of side-effects, then we will also need to think about entirely different prevention and support strategies for female patients."
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO 2018 Congress Official Congress hashtag: #ESMO18
This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.
1 Abstract 619PD_PR 'Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: a pooled analysis of 4 randomised trials' will be presented by Michael Davidson during Poster Discussion Session on Friday, 19 October 2018, 16:00 to 17:30 (CEST) in Room 21 - Hall B3. Annals of Oncology, Volume 29 Supplement 8 October 2018
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 18,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. ESMO is committed to offer the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide.
619PD_PR - Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: A pooled analysis of four randomised trials
M. Davidson1, A.D. Wagner2, K. Kouvelakis3, N. Starling1, I. Chau1, D. Watkins1, S. Rao1, C. Peckitt3, D. Cunningham1
1Gastrointestinal Department, Royal Marsden Hospital NHS Foundation Trust, London, UK, 2Medical Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, Switzerland, 3R&D,
Royal Marsden Hospital NHS Foundation Trust, London, UK
Background: Sex is a contributing factor to inter-patient variability of chemo metabolism and dose-response, potentially influencing both efficacy and toxicity. Use of a triplet chemo regimen comprising an anthracycline, platinum and fluoropyrimidine remains a standard option in first line treatment of advanced OG cancer. Comparative data on the effect of sex on chemo-related toxicity in this tumour type are lacking.
Methods: Data for pts randomised to ECF, ECX, EOF or EOX chemo within 4 UK-NCRI multicentre RCTs of first line treatment in advanced OG cancer were pooled. Demographic and outcome data, and prevalence of all grade and grade ?3 toxicity were compared between males and females. Adverse events and response rates were compared by Chi-squared test; survival outcomes by log-rank test.
Results: 1654 pts were included; 1328 males (80.3%) and 326 females (19.7%). Age and PS were equally distributed; gastric tumours were more prevalent in females (57.4 vs 34.1%). For toxicities captured commonly across all 4 trials there was no significant difference in all grade or grade ?3 toxicity between females and males (67.2 vs 62.8%; p=0.19). Females experienced significantly higher rates of nausea and vomiting, both all grade (89.3 vs 78.3%; p<0.001) and grade ?3 (16.7 vs 9.5%; p<0.001); all grade diarrhoea (53.8 vs 46.9%; p=0.027); all grade stomatitis (49.5 vs 40.7%; p=0.004) and all grade alopecia (81.4 vs 74.3%; p=0.009). There was a trend towards increased rates of grade greater than or equal to 3 neutropaenia and febrile neutropaenia (45.1 vs 40.4% and 11.8 vs 7.7% respectively), although significance was not reached. Males experienced significantly more all grade peripheral neuropathy (49.3 vs 42.6%; p=0.03). There was no difference in PFS or OS by sex; ORR was higher in males (46.6 vs 40.4%), which approached significance (p=0.051).
Conclusions: This represents the largest pooled analysis of sex effect on outcome and toxicity in advanced OG cancer pts treated with equivalent first line chemo. Females demonstrated significantly higher rates of a number of toxicities, primarily GI in nature, and a trend towards increased rates of neutropaenia. Such results suggest that further research on the impact of sex on the efficacy and toxicity of chemo is necessary.
Legal entity responsible for the study: Royal Marsden Hospital NHS Foundation Trust
Funding: National Institute of Health Research
Disclosure: N. Starling: Research funding AZ, BMS and Merck. Honoraria AZ. I. Chau: Advisory Board: Sanofi Oncology, Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Five Prime Therapeutics; Research funding: Janssen-Cilag, Sanofi Oncology, Merck-Serono, Novartis; Honorarium: Taiho, Pfizer, Amgen, Eli-Lilly. D. Cunningham: Research funding: Amgen, AstraZeneca, Bayer, Celgene, Merck-Serono, Medimmune, Merrimack, Novartis, Roche, Sanofi. All other authors have declared no conflicts of interest.
Annals of Oncology